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Kallikrein-related peptidases, in particular KLK4, 5, 6 and 7 (4e7), often have elevated
expression levels in ovarian cancer. In OV-MZ-6 ovarian cancer cells, combined expression
of KLK4e7 reduces cell adhesion and increases cell invasion and resistance to paclitaxel.
The present work investigates how KLK4e7 shape the secreted proteome (“secretome”)
and proteolytic profile (“degradome”) of ovarian cancer cells. The secretome comparison
consistently identified >900 proteins in three replicate analyses. Expression of KLK4e7 pre-
dominantly affected the abundance of proteins involved in cellecell communication.
Among others, this includes increased levels of transforming growth factor b-1 (TGFb-1).
KLK4e7 co-transfected OV-MZ-6 cells share prominent features of elevated TGFb-1
signaling, including increased abundance of neural cell adhesion molecule L1 (L1CAM).
Augmented levels of TGFb-1 and L1CAM upon expression of KLK4e7 were corroborated
in vivo by an ovarian cancer xenograft model. The degradomic analysis showed that
KLK4e7 expression mostly affected cleavage sites C-terminal to arginine, corresponding
to the preference of kallikreins 4, 5 and 6. Putative kallikrein substrates include chemo-
kines, such as growth differentiation factor 15 (GDF 15) and macrophage migration inhib-
itory factor (MIF). Proteolytic maturation of TGFb-1 was also elevated. KLK4e7 have a
pronounced, yet non-degrading impact on the secreted proteome, with a strong associa-
tion between these proteases and TGFb-1 signaling in tumor biology.
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Published by Elsevier B.V. Open access under CC BY-NC-ND license.17, 79104 Freiburg, Germany. Tel.: þ49 761 203 9615.
.uni-freiburg.de (O. Schilling).
vascular Surgery, University Heart Center Freiburg, Bad Krozingen, D-79194 Freiburg,
iochemical Societies. Published by Elsevier B.V.
3
Open access under CC BY-NC-ND license.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 6 8e8 2 691. Introduction how they shape the extracellular proteome andwhich proteo-Ovarian cancer accounts for 6% of all cancer-related deaths
despite its comparably low incidence rate (3% of solid tumors)
(Siegel et al., 2012). 90% of ovarian cancers are of epithelial
origin. Most women present with advanced stage disease
since they often remain asymptomatic in the early stage dis-
ease. Hence, the prognosis is poor with five-year survival rates
<20% (Roett and Evans, 2009). Kallikrein-related peptidases
(KLKs) are frequently over-expressed in ovarian cancer
(Borgo~no et al., 2004) and are suggested to be prognostic
markers (Obiezu and Diamandis, 2005). They solely comprise
a catalytic domain of approximately 25 kDa and have
trypsin-like or chymotrypsin-like specificity (Yousef and
Diamandis, 2003).
During the last decade, a series of publications showed
strong linkage between poor prognosis in ovarian cancer
and elevated expression of KLK proteases, including human
KLK 4 (Dong et al., 2001; Obiezu et al., 2001; Xi et al., 2004),
KLK5 (Diamandis et al., 2003; Kim et al., 2001; Michael et al.,
2005; Yousef et al., 2003a, 2003b), KLK6 (Diamandis et al.,
2003, 2000; Ghosh et al., 2004; Hoffman et al., 2002;
Kountourakis et al., 2008; Lu et al., 2004; Ni et al., 2004;
Santin et al., 2004; Shih Ie et al., 2007; Tanimoto et al., 2001;
White et al., 2009), and KLK7 (Kyriakopoulou et al., 2003;
Psyrri et al., 2008; Shan et al., 2006; Shigemasa et al., 2001;
Shih Ie et al., 2007; Tanimoto et al., 1999).
There exists comparably few data on the causative relation
between KLK expression and aggressiveness of this disease.
One of the first studies to investigate the impact of KLK prote-
ases on tumor cell behavior used the ovarian cancer cell line
OV-MZ-6, which lacks endogenous KLK expression. OV-MZ-6
were co-transfected to express KLK4e7 simultaneously
(Prezas et al., 2006). Combined expression of KLK4e7 led to
increased invasiveness in in vitro matrigel invasion assays
and elevated tumor burden in a xenograft model (Prezas
et al., 2006). Noteworthy, expression levels of KLK4e7 were
moderate, with antigen levels in the low ng/ml range in cell
culture supernatant, xenograft tumor tissue and tumor fluid.
A recent follow-up study showed that combined KLK4e7
expression decreases cell adhesion to vitronectin and fibro-
nectin while the resistance to paclitaxel, a cytotoxic agent
which is used as a chemotherapeutic for ovarian cancer,
was increased (Loessner et al., 2012). In good agreement,
several studies revealed that expression of KLK4e7 correlated
with the lack of response to paclitaxel in ovarian cancer pa-
tients (Dong et al., 2010; Oikonomopoulou et al., 2008; Xi
et al., 2004; Yousef and Diamandis, 2009).
As a post-translational modification, proteolysis acts in
both destructive and constructive manner. “Destructive” de-
scribes degradative function of proteolysis. In this context,
proteolysis is important for adjusting proteome composition
and protein turnover. “Constructive” refers to limited proteol-
ysis, which generates stable cleavage products that often
possess new functionality; examples include activation of
enzyme and cytokine precursors as in the case of transform-
ing growth factor b-1 (TGFb-1).
Despite numerous studies that correlate KLK expression
with cancer progression, it has remained largely unknownlytic cleavage events are mediated by their expression. Mass
spectrometry-based proteomics is a very powerful approach
to quantitatively survey proteome composition in different
biological samples (Aebersold and Mann, 2003). However,
such global approaches are not well suited for the analysis
of native or proteolytically generated protein termini as these
are typically overshadowed by more abundant native pep-
tides. Hence, specific enrichment techniques are employed
to accumulate terminal peptides. Proteomic strategies target-
ing proteolytic processing are referred as ‘degradomics’
(Lopez-Otın and Matrisian, 2007). One of the most powerful
degradomic approaches, targeting protein N-termini, has
been brought forward by Kleifeld et al. (2010) with widespread
applications in cell cultures (Jefferson et al., 2013; Prudova
et al., 2010; Tholen et al., 2011) and tissue samples (auf dem
Keller et al., 2013; Tholen et al., 2013). Typically, secretome
or proteome composition is studied in parallel by a global,
quantitative proteomics approach employing stable isotope
labeling. The combination of both strategies is crucial since
protease (over-) expression often leads to downstream effects
and altered protein abundance. Cleavage sites in quantita-
tively affected proteins may appear as up- or down-
regulated; however, they rather represent altered protein
abundance than affected proteolysis.
It has been shown that KLK proteases, including KLK4, 5, 6
and 7, degrade components of the extracellular matrix (ECM)
in vitro (Ghosh et al., 2004; Michael et al., 2005; Obiezu et al.,
2006; Ramani and Haun, 2008). However, in vitro studies using
purified proteases and individual substrate candidates are
intrinsically biased and fail to depict cell-contextual proteoly-
sis. The in vivo context differs considerably from the in vitro
situation through the presence of co-factors, inhibitors, and
the occurrence of downstream effects, such as perturbed acti-
vation cascades. Using the KLK4e7 co-transfected OV-MZ-6
cells, this study investigates how KLK4e7 contribute to the
extracellular proteome composition and which proteolytic
cleavage events are affected. Motivated by their important
roles in ovarian cancer, this is the first cell-contextual proteo-
mic and degradomic study of kallikrein proteases. Our results
highlight extracellular kallikrein activity, albeit without
massively elevated degradative proteolysis. Importantly,
expression of KLK4e7 leads to elevated TGFb-1 signaling
with concurrent effects, such as increased L1CAM expression,
and a previously described more motile cellular phenotype
(Loessner et al., 2012; Prezas et al., 2006).2. Materials and methods
2.1. Cell culture
The human ovarian cancer cell line OV-MZ-6 was established
from the tumor fluid (ascites) of a patient with serous adeno-
carcinoma of the ovary (Mobus et al., 1992) and used to stably
co-transfect expression vectors harboring human full-length
cDNA of kallikreins 4e7 (Prezas et al., 2006). OV-MZ-6 cells
transfected with an empty vector served as controls. Cells
were cultured in Dulbecco’s modified eagle medium (DMEM;
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 6 8e8 270PAN) supplemented with 10% fetal calf serum (FCS; PAN), 1%
non-essential amino acids, 1% MEM vitamins, 1% penicillin/
streptomycin, and 10mMHEPES (pH 7.5) at 37 C in humidified
air containing 5% CO2.
2.2. Collection of cell conditioned medium for proteomic
and degradomic analyses
Cell conditionedmedium (CCM)was generatedby incubationof
cells in serum-free medium to avoid overshadowing of serum
proteins. Cells were grown to 90% confluency as described
above.Themediumwas removed, andcellswerewashed thrice
withDMEM (without phenol red and FCS). Cellswere then incu-
bated in DMEM (1% non-essential amino acids, 1% MEM vita-
mins, 1% penicillin/streptomycin, 10 mM HEPES (pH 7.5);
without phenol red) for 1 h at 37 C. Then, this medium was
removed, and the cells were gently washed twice with DMEM
(without phenol redandFCS) and 20mlof fresh serum-freeme-
dium (as above) added. After 24 h, the CCMwas harvested, and
protease-inhibitors were added [1 mM trans-epoxysuccinyl-L-
leucylamido (4-guanidino)butane (E-64), 5 mM ethylene-
diaminetetraacetic acid (EDTA), 1 mM phenlymethansulfonyl-
flouride (PMSF)]. Cell debris was removed by centrifugation at
4500 rpmfor 5minat4 Candfiltration througha0.2mmsyringe
filter. Protein concentration was determined using a Bradford
(Bio-Rad) or bicinchonic acid (BCA) assay.
2.3. Quantitative proteome comparison
Quantitative proteome comparison by differential dimethyla-
tion was performed as described previously (Tholen et al.,
2013, 2011). Briefly, CCM was concentrated by ultra-filtration
(5 kDa molecular weight cut-off (MWCO; Vivascience) fol-
lowed by precipitation with acetoneemethanol or trichlorace-
tic acid. The protein pellet was re-solubilized in ice-cold
100 mM NaOH using ultrasonication. After adjusting the pH
to 8.0 using HEPES, the samples were trypsinized (1:100;
sequencing grade trypsin, Worthington; for 16 h at 37 C),
reduced (2 mM tris(2-carboxyethyl)phosphine (TCEP; Sigma),
1 h at 37 C), and alkylated (10 mM iodoacetamide (Sigma) at
37 C for 1 h followed by 5 mM dithiothreitol (DTT; Sigma),
20min at 22 C for quenching). Isotopic labels were introduced
by reductive dimethylation of primary amines using either
light (12COH2; Sigma) or heavy (
13COD2; Cambridge Isotopes)
formaldehyde (FA). Samples were incubated with 20 mM of
the given formaldehyde isotope and 20 mM of sodium cyano-
borohydride (ALD coupling solution, Sterogene) for 16 h at
37 C. Excess reagents were quenched with 20 mM glycine
(20min, 22 C). Equal amounts of heavy and light labeled sam-
ples were mixed, desalted using C18 solid phase extraction
(Waters) according to manufacturer’s instruction, and frac-
tionated by strong cation exchange (SCX) chromatography as
described previously (Tholen et al., 2011) prior to liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
analysis (see corresponding section).
2.4. Terminal Amine Isotopic Labeling of Substrates
Terminal Amine Isotopic Labeling of Substrates (TAILS)
(Kleifeld et al., 2010) was performed as described previously(Tholen et al., 2013, 2011). Briefly, the CCM was concentrated
by ultrafiltration (5 kDa MWCO) followed by precipitation
with acetoneemethanol or trichloracetic acid. The protein
pellet was re-solubilized in ice-cold 100 mM NaOH and 3 M
guanidine hydrochloride using ultrasonication. After adjust-
ing the pH to 8.0 using HEPES, the samples were reduced
(5 mM DTT for 1 h at 37 C), alkylated (15 mM iodoacetamide
in the dark for 30 min at 22 C) with quenching of excess
iodoacetamide (5 mM DTT for 30 min at 22 C). Samples
were labeled by dimethylation using 20 mM light (12COH2;
Sigma) or heavy (13COD2; Cambridge Isotopes) formaldehyde
in the presence of 20 mM NaCNBH3 (for 18 h at 37 C). After
quenching of excess reagents with 50 mM TriseCl, pH 7.5
(for 1 h at 37 C), samples were mixed at equal amounts,
acetone precipitated and re-solubilized with 100 mM ice-cold
NaOH as described for quantitative proteome comparison.
The pH was adjusted to 8.0 with HEPES-free acid, trypsinized
(1:100; for 18 h at 37 C), and purified using Sep-Pak C18
solid-phase extraction columns (Waters) according to manu-
facturer’s instructions. Samples were eluted in 80% acetoni-
trile, pH was adjusted to 7.0 and acetonitrile removed by
vacuum evaporation, followed by volume adjustment with
water. Internal peptides bearing free N-termini were coupled
to an aldehyde-functionalized polymer (Kleifeld et al., 2010)
in the presence of 50 mM sodium cyanoborohydride (Stero-
gene). Excess reagents were quenched with 100 mM glycine
for 1 h at room temperature. The sample was applied to a
10 kDa MWCO filter. The flow-through was desalted, fraction-
ated by strong cation exchange (SCX) chromatography, and
analyzed by LC-MS/MS.
2.5. LC-MS/MS analysis
For nanoflow-LC-MS/MS analysis, samples for quantitative
proteomic comparison were analyzed on a Qstar Elite (AB
Sciex) and TAILS samples for quantitative proteomic compar-
ison on an Orbitrap XL (Thermo Scientific GmbH) mass spec-
trometer. Both instruments were coupled to an Ultimate3000
micro pump (Thermo Scientific) with a flow rate of 300 nl/
min each. Buffer A was 0.5% acetic acid, and buffer B was
0.5% acetic acid in 80% acetonitrile (water and acetonitrile
were at least HPLC gradient grade quality). A gradient of
increasing organic proportion was used for peptide separa-
tion. Column-tips with 75 mm inner diameter and a length of
11 cm were self-packed (Olsen et al., 2004) with Reprosil-Pur
120 ODS-3 (Dr. Maisch, Ammerbuch, Germany). The MS oper-
ated in data dependent mode, with the SMART being used for
the QSTAR Elite. For the Orbitrap XL, each MS scan was fol-
lowed by amaximum of five MS/MS scans; in case of the Qstar
Elite of three MS/MS scans.
2.6. LC-MS/MS data analysis: quantitative proteome
comparison
RawQSTARLC-MS/MSdata inwiff formatwas converted to the
mzXML (Pedrioli et al., 2004) format, using mzWiff (version
4.3.1, http://sourceforge.net/projects/sashimi/files/mzWiff%
20(Analyst%20converter), with centroiding of MS1 and MS2
data, precursor charge determination, and deisotoping of
MS2 data. For spectrum to sequence assignment X! Tandem
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teome database consisted of human reviewed canonical uni-
prot sequences (without isoforms) downloaded from UniProt
on February 28, 2012. It consists of 20,240 real protein entries.
It was appended with an equal number of shuffled decoy en-
tries derived from the original human protein sequences. The
decoy sequences were generated with the software DB toolkit
(Martens et al., 2005). Two different searches were conducted
for light and heavy labeled peptides. X! Tandem parameters
included: asymmetric pre-cursor mass error of 0e200 ppm,
fragment ion mass tolerance of 0.2 Da, tryptic cleavage speci-
ficity with no missed cleavage sites, residue modifications:
cysteine carboxyamidomethylation (þ57.02 Da), lysine and
N-terminal dimethylation (light formaldehyde 28.03 Da; heavy
formaldehyde 34.06 Da); no variablemodifications. X! Tandem
results were further validated by PeptideProphet (Keller et al.,
2002) at a confidence level of >95%. Peptides were assembled
to proteins using ProteinProphet (Nesvizhskii et al., 2003). For
relative peptide and protein quantification ASAPRatio (Li
et al., 2003) was used. ASAPRatio results were validated by
XPRESS (Han et al., 2001) as described previously (Tholen
et al., 2013). Proteins were only considered if ASAPratio and
XPRESS yielded convergent results. Mass tolerance for quanti-
fication was 0.1 Da. Ratios of each dataset were calculated as
KLK expression over controls. ASAPratio data was log2-trans-
formed. ASAPRatio p-values were merged using Fisher’s exact
test. A combined p-value was calculated according to the c2
distribution. Protein abundance was considered to be signifi-
cantly altered if the following conditionsweremet: (A) the pro-
tein was identified in all three replicate experiments, (B)
merged ASAPRatio p-value < 0.1, (C) protein abundance was
either increased or decreased in all three replicate experi-
ments. Since this work focuses on secreted proteins, only the
secreted proteins were further considered. A protein was
considered to be secreted or cell surface localized if its GO
(GeneOntology) cellular compartment information or its Swis-
sProt localization information featured one of the following
terms: secreted, extracellular, surface, integral to membrane.
2.7. LC-MS/MS data analysis: Terminal Amine Isotopic
Labeling of Substrates
Orbitrap LC-MS/MS data in raw format was converted to the
mzXML (Pedrioli et al., 2004) format, using msconvert
(Kessner et al., 2008) with centroiding of MS1 and MS2 data,
and deisotoping ofMS2data. For spectrum to sequence assign-
ment X! Tandem (Version 2010.12.01) (Craig and Beavis, 2004)
was used with the same database described for “LC-MS/MS
data analysis: quantitative proteome comparison”. Two
different searches were conducted for light and heavy labeled
peptides. X! Tandemparameters included: pre-cursormass er-
ror of 10 ppm, fragment ion mass tolerance of 0.3 Da, semi-
specific cleavage C-terminal to arginine residues (“Semi Arg-
C specificity”) with up to threemissed cleavages, residuemod-
ifications: cysteine carboxyamidomethylation (þ57.02 Da),
lysine and N-terminal dimethylation (light formaldehyde
28.03 Da; heavy formaldehyde 34.06 Da); no variable modifica-
tions. X! Tandem resultswere further validated by PeptidePro-
phet (Keller et al., 2002) at a confidence level of >95%. For
relative peptide and protein quantification ASAPRatio (Liet al., 2003) was used. ASAPRatio results were validated by
XPRESS (Zhang et al., 2003) as described previously (Tholen
et al., 2013). Peptides were only considered if ASAPratio and
XPRESS yielded convergent results. Two TAILS experiments
were performed. Ratios of each dataset were calculated as
KLK expression over controls. Ratios were divided into the
following quantiles 0e20, 20e80, and 80e100. N-termini were
considered as decreased if found in the quantile 0e20 in both
replicates or as increased if found in the quantile 80e100 in
both replicates. Further analysis focused particularly on
secreted proteins as described in “LC-MS/MS data analysis:
quantitative proteome comparison”.2.8. Western blotting
The CCM was prepared as described above. Total cell extracts
were prepared by on plate lysis with 50 mM TriseCl, pH 8.0,
150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS. Samples
were separated by SDS-polyacrylamide gels (see Figures for
details) and transferred on polyvinylidene fluoride (PVDF)
membrane using a semidry blotting system (BioRad). Primary
antibodies [PEDF (1:1000, R&D Systems, AF1177), L1CAM
(1:1000, R&D Systems, AF277); LAP (TGFb-1 prodomain)
(1:1000, R&D Systems, AF246NA); tubulin (1:1000, Sigma,
T6199), TGFb-1 (1:200, R&D Systems, AF7555)] were incubated
for 18 h at 4 C. After washing, themembraneswere incubated
for 18 h at 4 C with horseradish peroxidase-coupled second-
ary antibodies (goat, Dianova or sheep, Sigma). After further
washing, the membranes were developed with the West Pico
chemiluminescent substrate (Pierce), and peroxidase activity
detected with a LumiImager device (Roche).2.9. Immunohistochemical analysis of tumor xenografts
To evaluate the relevance of LAP/TGFb-1 and L1CAMexpression
in vivo, serial sections (5 mm) of tumor xenografts derived from a
recentlydevelopedovariancanceranimalmodel (Loessneretal.,
2013) were obtained and immunohistochemically processed.
Briefly, antigen retrieval was performed by 95 C treatment in
0.01 M TriseEDTA buffer (pH 8.0) followed by incubation of
anti-LAP (R&D Systems, AF246NA) and anti-L1CAM (R&D Sys-
tems, AF277) antibodies (5 mg/ml) for 1 h at room temperature.
The horseradish peroxidise (anti-goat) polymer detection sys-
tem with 3,30-diaminobenzidine as the chromogen (R&D Sys-
tems) was used. Sections were counterstained with Mayer’s
hematoxylin. Goat IgG (SigmaeAldrich) replacing the primary
antibodies served as negative control. Human-derived liver
metastasis served as positive control staining imaged using a
widefield microscope (LaborLux, Leitz; DXM1200C digital cam-
era, Nikon; ACT-1C software v.1.01) with a 20 air objective.3. Results and discussion
3.1. Global proteome comparison
3.1.1. Overview and overlap of individual replicates
Since KLKs are secreted proteases, we initially aimed to inves-
tigate how their expression modifies the extracellular
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cates were performed for the global secretome comparison.
In each case, CCM from KLK4e7 co-transfected OV-MZ-6 cells
was compared to CCM of controls. Differential labeling with
isotopic formaldehyde variants was performed for quantita-
tive comparison. These experiments identified and quantified
1390, 1474, and 1477 proteins respectively (Sup. Tables S1eS3).
Based on gene ontology (GO) and SwissProt annotation the
fraction of secreted and/or cell surface-associated proteins
was 26e27%. These values correspond well to the fraction of
extracellular and/or transmembrane proteins that were iden-
tified from the CCM of lung cancer cells (Planque et al., 2009),
breast cancer cells (Kulasingam and Diamandis, 2007) and
mouse embryonic fibroblasts (Tholen et al., 2011). In each
replicate, the fold-change (Fc) values (log2 of light to heavy ra-
tios) followed a near normal distribution with most proteins
displaying none or very little quantitative alteration
(Figure 1aec). These findings suggest that expression of
KLK4e7 results in subtle proteome alterations rather than
gross degradation.
In order to delineate consistent proteome changes as a
result of KLK expression, this work focuses on proteins that
were identified across all three replicates. In total, this was
the case for 928 proteins (Figure 1d, Sup. Table S4), of which
273 are annotated as being secreted or cell surface-Figure 1 e (aec) Distribution of fold-change values (log2 of light:heavy ratio
Overlap of the three replicate global proteome comparison experiments. 92
experiments.associated. The three replicates displayed a high reproduc-
ibility of protein quantitation with correlation coefficients be-
tween 0.67 and 0.80 (not shown).
3.1.2. Quantitatively affected proteins
Chemical stable isotope labeling was used to allow for relative
quantitation of peptides and proteins. The software ASAPRa-
tio was used to calculate peptide ratios togetherwith a p-value
to denote the statistical significance of a protein being quanti-
tatively affected (Li et al., 2003). ASAPRatio p-values of the
three replicates were combined as previously described
(Tholen et al., 2013) to yield a merged p-value. Proteins were
considered as being quantitatively affected if the merged p-
value was less than 0.1 in agreement with the original ASAP-
Ratio publication (Keller et al., 2002). Secondly, an increase
or decrease by more than 50% in all three replicates must be
observed. Lastly, peptide and protein ratios were manually
inspected. Of the 273 potentially secreted or shed proteins
that were identified in all three replicates, 45 proteins fulfilled
these criteria (Table 1).
Out of the 45 significantly affected proteins, 39 were
increased in abundance and only 6 were decreased in abun-
dance. These findings suggest that kallikreins 4e7 expression
does not result in major degradation, although biochemically
various kallikreins are able to degrade proteins, such ass) for the three replicate global proteome comparison experiments. (d)
8 proteins were consistently identified and quantified in all three
Table 1 e Significantly affected proteins by KLK4e7 expression. Uniprot ID and recommended name according to Uniprot database (Uniprot
Consortium, 2013). p-value denotes the significance of a protein being quantitatively affected. p-values of individual experiments were calculated
by ASAPratio (Li et al., 2003) and combined using Fisher’s method, resulting in a merged p-value. The cutoff of 0.1 was chosen in agreement with
the ASAPratio original publication (Li et al., 2003). Fc-value (log2 of light:heavy ratio) denotes the average Fc-value of the three replicates with
the corresponding standard deviation value in the following column.
Uniprot p-value Fc-value Std. dev. Name
P41222 0.000 4.1 0.8 Prostaglandin-H2 D-isomerase
Q7Z7G0 0.000 4.4 1.1 Target of Nesh-SH3
P33908 0.000 2.4 0.4 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA
P26022 0.000 3.4 0.2 Pentraxin-related protein PTX3
O43405 0.000 3.7 1.1 Cochlin
P36955 0.000 3.6 0.3 Pigment epithelium-derived factor (PEDF)
P24592 0.001 3.1 1.1 Insulin-like growth factor-binding protein (IGFBP) 6
P05997 0.001 4.9 0.5 Collagen alpha-2(V) chain
P09341 0.001 2.5 1.6 Growth-regulated a protein (Gro-a, C-X-C motif chemokine 1, CXCL1)
P17936 0.001 2.7 1.3 Insulin-like growth factor-binding protein (IGFBP) 3
P07711 0.002 2.2 0.2 Cathepsin L1
P53634 0.002 2.2 0.3 Dipeptidyl peptidase 1
P01034 0.003 1.9 0.2 Cystatin-C
P10646 0.003 2.1 0.1 Tissue factor pathway inhibitor
Q9UBG0 0.004 2.6 0.9 C-type mannose receptor 2
Q08629 0.004 2.1 0.5 Testican-1
P49746 0.004 2.4 0.9 Thrombospondin-3
P55268 0.004 2.7 0.8 Laminin subunit b-2
P49755 0.005 1.6 1.1 Transmembrane emp24 domain-containing protein 10
P13987 0.005 1.7 0.5 CD59 glycoprotein
O00300 0.009 3.6 1.7 Osteoprotegerin
O94907 0.009 2.1 0.5 Dickkopf-related protein (DKK)-1
P01024 0.010 2.2 0.6 Complement C3
P32004 0.010 2.0 0.3 Neural cell adhesion molecule L1
Q9H3T2 0.013 1.4 1.3 Semaphorin-6C
P12109 0.015 1.9 0.6 Collagen a-1(VI) chain
Q96EU7 0.015 2.1 2.4 C1GALT1-specific chaperone 1
Q99542 0.025 1.6 0.5 Matrix metalloproteinase-19
P09603 0.027 1.6 1.4 Macrophage colony-stimulating factor (MCSF)-1
O95407 0.033 1.5 0.4 Tumor necrosis factor receptor superfamily member 6B
Q9BTY2 0.038 1.5 0.5 Plasma alpha-L-fucosidase
P01137 0.041 1.6 0.5 Transforming growth factor (TGF)b-1
Q14563 0.042 1.7 0.2 Semaphorin-3A
P02786 0.043 1.9 0.1 Transferrin receptor protein 1
Figure 2 e Peptide mapping for collagen XVIII. Tryptic collagen
XVIII peptides that were identified in the global secretome
comparison are mapped on the collagen XVIII sequence. In all three
replicates, peptides cluster in the C-terminal non-collagenous region,
which encompasses the anti-angiogenic cleavage product endostatin.
S, signal peptide; NC, non-collagenous domain. The color scale
indicates the Fc-values of the individual peptides.
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et al., 2005). Rather, KLK4e7 expression appears to regulate
cellecell communication. This notion was supported upon
closer inspection of the affected proteins. Examples of
affected proteins with roles in cellecell communication
include IGFBP-3 and -6, semaphorins 3A and 6C, osteoprote-
gerin, dickkopf-related protein 1 (DKK-1), C-X-C motif chemo-
kine 1 (CXCL1), macrophage colony stimulating factor 1
(MCSF-1), pigment epithelium-derived factor (PEDF), latent
TGFb binding protein 3 (LTGFBP-3), and TGFb-1.
On the other hand, only few ECM components or matricel-
lular proteins were affected, such as cochlin, laminin b2, col-
lagens XVIII and V. For collagen XVIII, almost all identified
peptides mapped to its non-collagenous C-terminal domain,
which includes the anti-angiogenic cleavage product endosta-
tin (Figure 2). Similarly, for collagen V, almost all identified
peptides mapped to its non-collagenous C-terminal prodo-
main (data not shown). These observations highlight the
importance of peptide mapping for the functional interpreta-
tion of proteomic data.
To support our quantitative proteomic results, we vali-
dated the differential ratios for PEDF, thrombospondin-1,L1CAM, and TGFb-1 by immunoblotting. For all four proteins,
immunoblotting results are in line with quantitative proteo-
mic results (Figure 3). PEDF massively increases in abundance
upon combined expression of KLK4e7 (Figure 3a) whereas
Figure 3 e (a,b) Western blot detection of PEDF and
thrombospondin-1 in cell conditioned medium. 30 mg proteome were
used with a 12.5% reducing SDS-PAGE. (c) Western blot detection
of LAP/TGFb-1 in cell conditioned medium. 8 mg proteome were
used with a 12.5% reducing SDS-PAGE. The primary antibody was
directed against the LAP domain (prodomain). In line with previous
reports (Dubois et al., 1995), the w55 kDa band is thought to
represent proTGFb-1 whereas the predominant w40 kDa band is
thought to represent LAP. The elevated size in comparison to the
primary sequence is thought to stem from glycosylation (Brunner
et al., 1992; Dubois et al., 1995). (d) Western blot detection of mature
TGFb-1 (disulfide linked dimer) in cell conditioned medium. 30 mg
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TGFb-1 are discussed in detail below.
A vast body of literature links kallikrein expression to un-
favorable prognosis in different tumor entities (see also
Introduction). Based on this general picture, we investigated,
whether affected proteins rather bear a pro- or anti-
tumorigenic signature. However, a predominant pro- or
anti-tumorigenic effect of KLK expression was not detected.
For example, the group of proteins with increased abun-
dance features tumor suppressors such as PEDF (Becerra
and Notario, 2013) as well as tumor-promoting proteins,
such as DKK-1 (Pinzone et al., 2009; Yang et al., 2013). The
present data shows a prominent effect of KLK 4e7 expres-
sion on proteins with relevant roles in tumor biology but
without a clear pro- or anti-tumorigenic signature. Accord-
ingly, the proteomic data does not necessarily imply that
expression of KLK4e7 has a predominant pro-tumorigenic
effect.
3.1.3. Transforming growth factor b-1 signaling
TGFb-1 plays a central role in cancer biology. The biological
and cellular context determines the role of TGFb-1 in tumori-
genesis, which can be either tumor-promoting or tumor-
suppressing (Joshi and Cao, 2010). In early stages of tumori-
genesis, TGFb-1 is thought to be tumor suppressive through
pro-apoptotic activity. In later stages of tumorigenesis,
TGFb-1 is thought to facilitate metastasis by promoting cell
migration and invasion in a process resembling an
epithelial-mesenchymal transition (EMT) (Heldin et al., 2012).
TGFb-1 is synthesized as an inactive precursor with an N-
terminal prodomain (also called latency-associated protein,
LAP), which is proteolytically removed for activation of the
C-terminal TGFb-1 domain. Cleavage is typically performed
by furin-like proteases (Dubois et al., 1995), although acti-
vating cleavage by KLK proteases has been suggested
(Emami and Diamandis, 2007; Matsumura et al., 2005). LAP
covalently binds to LTGFBPs through disulfide bonds
(Hyyti€ainen et al., 2004). LTGFBPs further bind to ECMproteins,
thereby spatially fixing latent TGFb. In the present study,
elevated levels of LAP/proTGFb-1 were supported by immuno-
blotting using an antibody that targets LAP (Figure 3c). Sec-
ondly, elevated levels of mature TGFb-1 were corroborated
by immunoblotting using an antibody that targets the actual
TGFb-1 domain (Figure 3d). Finally, N-terminal degradomics
showed TGFb-1 activation (see corresponding section). Collec-
tively, these findings suggest increased TGFb-1 signaling.
TGFb-1 signaling is known to cause increased L1CAM
expression (Kiefel et al., 2012). We corroborated L1CAM levels
elevated by immunoblotting (Figure 3e). There are twoproteome were used with a 12.5% non-reducing SDS-PAGE. The
primary antibody was directed against the actual TGFb-1 domain. In
addition, N-terminal degradomics showed TGFb-1 activation (see
corresponding section). (e) Western blot detection of L1CAM in cell
conditioned medium (CCM) and total cell lysate, including cell
surface proteins. 8 mg (CCM) and 12 mg proteome (total cell lysate),
respectively, were separated with a 7.5% reducing SDS-PAGE. The
molecular weight of 220 kDa for L1CAM is higher than expected but
in line with previous reports (Li and Galileo, 2010).
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 6 8e8 2 75possible reasons for the raised levels of the shed L1CAM ecto-
domain: increased cell-surface proteolysis (with subsequent
depletion of membrane bound L1CAM) or elevated levels of
cell-associated L1CAM possibly representing higher L1CAM
expression. Western blotting showed higher cell-associated
levels of L1CAM (Figure 3e) suggesting its increased
expression.
Importantly, elevated levels of LAP/proTGFb-1 and L1CAM
upon expression of KLK4e7 were corroborated in vivo by
immunohistochemical analysis of tumor xenografts derived
from an ovarian cancer animal model (Loessner et al., 2013)
(Figure 4).
The cellular phenotype of the KLK4e7 co-expressing
ovarian cancer cells also supports increased levels of TGFb-1
signaling. These cells are less adhesive and more invasive
than their wild type counterparts (Loessner et al., 2012;
Prezas et al., 2006). In good agreement, expression of KLK4 in
PC3 prostate cancer cells leads to amoremigratory phenotype
(Veveris-Lowe et al., 2005). Similarly, expression of KLK6 in
murine keratinocytes results in amoremigratory and invasive
behavior (Klucky et al., 2007). In epithelial cells, TGFb-1 is
known to induce a more motile cellular phenotype (Kalluri
and Weinberg, 2009), which is considered a hallmark of
TGFb-1 signaling. A prototypical feature of TGFb-1 signaling
is loss of epithelial cadherin (E-cadherin) expression. Howev-
er, previous studies have determined that the OV-MZ-6 cell
line does not express E-cadherin ab initio and represents the
advanced disease stage (Loessner et al., 2012, 2010).
In summary, our quantitative secretome analysis shows
elevated LAP/proTGFb-1 expression in OV-MZ-6 cells co-
expressing KLK4e7. This is validated in vivo using tumorFigure 4 e Immunohistochemical detection of TGFb-1 and L1CAM expre
OV-MZ-6 cell and control tumors. A positive staining for both proteins w
KLK4e7 expression. Scale bars, 50 mm.xenografts. Several lines of evidence further support elevated
TGFb-1 signaling, including identification of mature, bioactive
TGFb-1, increased L1CAM expression, and a previously identi-
fied more motile cellular phenotype (Loessner et al., 2012;
Prezas et al., 2006). proTGFb-1 activation by KLK proteases
has been proposed (Emami and Diamandis, 2007;
Matsumura et al., 2005). Our study shows a strong association
between KLK expression and TGFb-1 signaling in a cellular
context.
3.2. Quantitative profiling of proteolytic cleavage sites
To identify cleavage events that are overrepresented upon
expression of KLK4e7, Terminal Amine Isotopic Labeling of
Substrates (TAILS) was used (Kleifeld et al., 2010). TAILS is a
proteomic method that specifically analyzes protein N-
termini, including proteolytically generated N-termini.
Through stable isotopic labeling, the N-terminome of kalli-
kreins 4e7 co-expressing OV-MZ-6 cells was quantitatively
compared to the N-terminome of the corresponding control
cells. More specifically, this analysis focuses on the cellular
secretome.
3.2.1. Overview and overlap of individual TAILS replicates
Two replicates were performed for the N-terminal analysis
based on CCM from OV-MZ-6 cells that express KLK4e7 in
comparison to OV-MZ-6 vector control cells. These experi-
ments identified and quantified 2435 and 1402 protein N-
termini respectively (Sup. Tables S5, S6). Based on GO and
SwissProt annotation, 41% and 34% map to secreted and/or
cell surface-associated proteins. These fractions are slightlyssion in xenografts derived from mice bearing KLK4e7 co-transfected
as detected in the cytoplasm, with a more intense staining upon
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possibly indicating the importance of proteolysis as a post-
translational modification in the extracellular milieu.
Most N-termini display Fc-values (log2 of light:heavy ratio)
close to 0 indicating that they were not quantitatively affected
by expression of KLK4e7 (Figure 5). This observation is in line
with the global proteome comparison, which also highlights
that kallikreins 4e7 expression does not lead to an excessive
increase in bulk proteolysis. Both replicates showed few cleav-
age sites with Fc-values <2. At the same time, there was a
substantial amount of cleavage sites with Fc-values >þ2.
This bias indicates an elevated proteolytic processing in the
cellular microenvironment upon expression of KLK4e7,
despite the aforementioned absence of excessively increased
bulk proteolysis.
The two TAILS experiments display an overlap of 589 N-
termini (Figure 5c). The quantitation (as displayed by the cor-
responding Fc-values) of these 589 shared identification
shows good reproducibility with a correlation coefficient of
0.71 (data not shown). This number is in line with the correla-
tion coefficients that were determined for the replicates of the
global proteome analysis.
3.2.2. Kallikreins 4e7 expression yields a “post-arginine”
specificity fingerprint
Proteolytic enzymes have characteristic specificities. As out-
lined by Debela et al. (2008), KLK4, KLK5 and KLK6 preferen-
tially cleave C-terminal to arginine whereas KLK7 displays
chymotryptic specificity (preferred cleavage C-terminal to
aliphatic and aromatic residues). Borgono et al. corroborate
KLK4e7 specificity (Borgo~no et al., 2007). At the same time,
Debela et al. as well as Yoon et al. have shown that KLK7
cleaves post arginine despite its chymotryptic preference
(Debela et al., 2006; Yoon et al., 2007). In the present study,
the majority of enriched cleavage sites (Fc-value > 1) in
both replicates occurred C-terminal to an arginine residue
(Figure 6) and only few chymotryptic cleavage sites were
observed. This specificity fingerprint corresponds well to
the annotated preference of KLK4, KLK5 and KLK6, and
possibly also KLK7. These findings strongly indicate a prom-
inent KLK activity in the secretome of KLK4e7 co-
transfected OV-MZ-6 cells. The high representation of
trypsin-like as opposed to chymotrypsin-like activity is not
surprising since 3 of the 4 enzymes (KLK4/5/6) have predom-
inant tryptic activity.Figure 5 e (aeb) Distribution of fold-change values (log2 of light:heavy rati
two replicate N-terminomic experiments. 589 cleavage sites were consisten3.2.3. Identification of putative KLK cleavage sites
Proteolysis in OV-MZ cell conditioned mediumwas profiled to
identify putative KLK substrates. Strict criteria were chosen to
select neo-N-termini as possible KLK cleavage sites:
 neo-N-terminus identified in both replicates (589 cleavage
sites)
 maps to a protein that is annotated as being secreted or cell
surface-associated according to GO or SwissProt annotation
(236 of the 589 cleavage sites)
 quantitatively enriched upon KLK expression (Fc-
value > 1.0, 91 of the 236 cleavage sites)
 cleavage occurs C-terminal to an arginine (KLK4, KLK5,
KLK6, and possibly also KLK7 specificity) or aromatic resi-
dues (KLK7 specificity); our analysis was restricted to canon-
ical KLK specificity (Debela et al., 2008) (61 of the 91 cleavage
sites).
 corresponding protein levels are not found to be elevated in
global secretome comparison
 neo-N-terminus does not represent removal of signal pep-
tide or initiator methionine
14 cleavage sites in a total of 12 different proteins entirely
fulfill these strict criteria and represent putative KLK sub-
strates (Figure 7). Kallikrein dependent proteolytic processing
of several cell signaling proteins was observed, including
growth differentiation factor 15 (GDF-15), macrophage inhibi-
tory factor (MIF), semaphorin 3C and stanniocalcin-1.With the
exception of agrin, kallikrein dependent proteolysis was not
observed for matricelullar proteins or ECM components. The
focus on cellecell communication was in line with the results
obtained by global proteomic comparison. Together, both
findings strengthen the notion of proteolysis being a regulato-
ry event in cancer cell biology.
To a large extent, KLK dependent proteolytic events appear
to occur in structurally accessible sites, including domain
linker regions present in agrin, annexin A2 and tyrosine-
protein kinase receptor UFO. Similarly, N- and C-terminal re-
gions of proteins are often structurally accessible. In this
context, N-terminal processing of cathepsin Z and sema-
phorin 3C likely occurs at a structurally accessible site. Prote-
olysis at structurally accessible sites does not necessitate prior
unfolding, and thus, suggests a regulatory rather than a degra-
dative function.os) for the two replicate N-terminomic experiments. (c) Overlap of the
tly identified and quantified in both experiments.
Figure 6 e Specificity fingerprint of cleavage sites that are induced by expression of KLK4e7 (quantile 80e100). The white line depicts the scissile
peptide bond. The X-axis shows amino acid positions in relation to the cleavage site. Schechter and Berger nomenclature was used (Schechter and
Berger, 1966). Heat map generated as described previously (Schilling et al., 2011). Sequence logos were generated with the iceLogo software
(Colaert et al., 2009).
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platelet-derived growth factor subunit A (PDGFA) and
stanniocalcin-1 occur after several basic residues (arginine
or lysine). Such sites are typically considered to be targeted
by furin-like proteases, a group which includes proprotein
convertases. Specificity profiling of KLK4e6 showed that
only KLK6 has a pronounced preference for pairs of basic res-
idues (Borgo~no et al., 2007; Debela et al., 2008). The present
analysis cannot distinguish increased furin-like activity as a
downstream effect of initial KLK activity. However, the speci-
ficity fingerprints (Figure 6) do not show an increased occur-
rence of cleavage sites at dibasic motives but rather support
increased activity of trypsin-like KLK proteases.
Using a cell model of ovarian cancer, our data shows pro-
teolytic remodeling of the cellular microenvironment by KLK
proteases, with a prominent focus on proteins mediating
cellular communication. It is beyond the scope of the present
work to determine the functional consequences stemming
from KLK dependent proteolytic processing. However, it has
been shown that proteases can inactivate or functionally
convert chemokines through proteolytic processing and gen-
eration of stable cleavage products (Broxmeyer et al., 2012;
McQuibban et al., 2000).
3.2.4. TGFb-1 maturation
Global quantitative proteomic comparison strongly indicates
a pronounced effect of KLK expression on TGFb-1 levels andsubsequent TGFb signaling (see corresponding section). In
good agreement, the N-terminomic analysis revealed sub-
stantially elevated amounts of the mature N-terminus of the
TGFb-1 cytokine domain (Figure 8). As stated above, increased
occurrence of mature TGFb-1 most likely reflects an elevated
abundance of the precursor form rather than increased pro-
teolytic processing. The corresponding identification of
mature TGFb-1 cytokine domain by N-TAILS complements
this finding and points to increased levels of bioactive TGFb-
1 rather than a sheer accumulation of its inactive precursor.4. Conclusion
This study focused on the impact of KLK4e7 expression in the
OV-MZ-6 ovarian cancer cells as numerous studies suggest
that KLKs are associated with ovarian cancer. This study ad-
dresses the contribution of kallikreins in shaping the cellular
microenvironment. The proteomic and degradomic analyses
highlight the absence of excessively increased bulk proteoly-
sis but rather support the notion of proteolysis being a regula-
tory event in cellecell communication. For example, KLK4e7
expression leads to elevated levels of the pro-inflammatory
proteins CXCL1 and MCSF-1. Putative KLK substrates include
cytokines, such as GDF-a and MIF. Both experimental setups
corroborate induced TGFb-1 signaling. While global secretome
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Figure 7 e Putative substrates of KLK4e7. Cleavage sites are annotated by arrows. Criteria for selection of cleavage sites are described in the text.
Abbreviations used: A, annexin-like; C1, peptidase C1 domain; GDF, growth differentiation factor; E, epidermal growth factor-like; Fn,
fibronectin type III-like; I: immunoglobulin I-set-like; K, kazal-like; L, laminin-like; MIF, macrophage migration inhibitory factor; MHC, major
histocompatibility complex-like; Nta, N-terminal agrin; P, prodomain; PCSKI, proprotein convertase 1 inhibitor; PDGFA, platelet-derived
growth factor subunit A; Pk, protein tyrosine kinase-like; PV; platelet-derived growth factor-like/vascular endothelial growth factor-like; Sem,
semaphorin-like; St: stanniocalcin-like; T, transmembrane; Tb, transforming growth factor-b-like; Tf: transferrin-like.
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Figure 8 e The N-terminus of mature TGFb-1 was identified in both
TAILS replicates with elevated abundance upon combined expression
of KLK4e7. The tandem mass spectra of the identified sequence
ALDTNYCFSSTEKNCCVR (N-terminus of mature TGFb-1) is
shown. This finding corroborates elevated levels of mature, bioactive
TGFb-1.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 6 8e8 2 79revealed substantially elevated amounts of the mature N-ter-
minus of the TGFb-1 cytokine domain, underlining the
increased levels of bioactive TGFb-1, which possibly result in
the previously described more motile phenotype of kallikrein
4e7 co-expressing OV-MZ-6 cells (Loessner et al., 2012; Prezas
et al., 2006). This study emphasizes the major impact of KLK
proteases on the extracellular proteome in the tumor micro-
environment of ovarian cancer.Conflict of interest
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